{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:01:54Z","timestamp":1791925314833,"version":"4.3.4"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.bioorg.2020.104612","type":"journal-article","created":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T16:23:11Z","timestamp":1610036591000},"page":"104612","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"special_numbering":"C","title":["Computational and Synthetic approach with Biological Evaluation of Substituted Quinoline derivatives as small molecule L858R\/T790M\/C797S triple mutant EGFR inhibitors targeting resistance in Non-Small Cell Lung Cancer (NSCLC)"],"prefix":"10.1016","volume":"107","author":[{"given":"Kshipra S.","family":"Karnik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aniket P.","family":"Sarkate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shailee V.","family":"Tiwari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajaram","family":"Azad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prasad V.L.S.","family":"Burra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pravin S.","family":"Wakte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2020.104612_b0005","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1023\/A:1008209720526","article-title":"Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trial","volume":"12","author":"Voldborg","year":"1997","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bioorg.2020.104612_b0010","first-page":"F217","article-title":"Protein tyrosine kinases and cancer","volume":"1333","author":"Kolibaba","year":"1997","journal-title":"BBA"},{"key":"10.1016\/j.bioorg.2020.104612_b0015","doi-asserted-by":"crossref","first-page":"46265","DOI":"10.1074\/jbc.M207135200","article-title":"Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4-Anilinoquinazoline Inhibitor","volume":"277","author":"Stamos","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bioorg.2020.104612_b0020","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/S0092-8674(02)00963-7","article-title":"Crystal Structure of the Complex of Human Epidermal Growth Factor and Receptor Extracellular Domains","volume":"110","author":"Ogiso","year":"2002","journal-title":"Cell"},{"key":"10.1016\/j.bioorg.2020.104612_b0025","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1200\/JCO.2005.11.890","article-title":"Critical Update and Emerging Trends in Epidermal Growth Factor Receptor Targeting in Cancer","volume":"23","author":"Baselga","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2020.104612_b0030","first-page":"2349","article-title":"Anticancer activity and drug likeliness of quinoline through insilico docking against cervical and liver cancer receptors","volume":"3","author":"Santhi","year":"2016","journal-title":"Indian J. Med Res. Pharm. Sci."},{"key":"10.1016\/j.bioorg.2020.104612_b0035","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/nrc2088","article-title":"Epidermal growth factor receptor mutations in lung cancer","volume":"7","author":"Sharma","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bioorg.2020.104612_b0040","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1007\/s00044-017-1798-9","article-title":"Design, synthesis and biological evaluation of new 4-(4-substitutedanilino)quinoline derivatives as anticancer agents","volume":"26","author":"Abdellatif","year":"2017","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.bioorg.2020.104612_b0045","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1097\/CCO.0000000000000164","article-title":"Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer","volume":"27","author":"Liao","year":"2015","journal-title":"Curr. Opin. Oncol."},{"key":"10.1016\/j.bioorg.2020.104612_b0050","first-page":"i10","article-title":"Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors","volume":"29","author":"Westover","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2020.104612_b0055","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1634\/theoncologist.12-3-325","article-title":"Second-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer","volume":"12","author":"Sequist","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.bioorg.2020.104612_b0060","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.ccell.2015.05.012","article-title":"The Next Wave of EGFR Tyrosine Kinase Inhibitors Enter the Clinic","volume":"27","author":"Politi","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bioorg.2020.104612_b0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-018-0778-0","article-title":"Third generation EGFR TKIs: current data and future directions","volume":"17","author":"Tan","year":"2018","journal-title":"Mol. Cancer."},{"key":"10.1016\/j.bioorg.2020.104612_b0070","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.critrevonc.2017.07.003","article-title":"Third generation EGFR TKIs in EGFR-mutated NSCLC: Where are we now and where are we going","volume":"117","author":"Russo","year":"2017","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.bioorg.2020.104612_b0075","doi-asserted-by":"crossref","first-page":"695","DOI":"10.21037\/tlcr.2016.12.02","article-title":"Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in T790M-positive non-small cell lung cancer: review on emerged mechanisms of resistance","volume":"5","author":"Minari","year":"2016","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.bioorg.2020.104612_b0080","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ejmech.2017.05.027","article-title":"Recent updates on third generation EGFR inhibitors and emergence of fourth generation EGFR inhibitors to combat C797S resistance","volume":"142","author":"Patel","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2020.104612_b0085","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.canlet.2016.11.008","article-title":"EAI045: The fourth-generation EGFR inhibitor overcoming T790M and C797S resistance","volume":"385","author":"Wang","year":"2017","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bioorg.2020.104612_b0090","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.lungcan.2017.02.020","article-title":"Synergy between next generation EGFR tyrosine kinase inhibitors and miR\u201334a in the inhibition of non-small-cell lung cancer","volume":"108","author":"Zhao","year":"2017","journal-title":"Lung Cancer."},{"key":"10.1016\/j.bioorg.2020.104612_b0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112522","article-title":"Design, Synthesis and Biological Evaluation of 4-Aniline QuinazolineDerivativesConjugated with Hydrogen Sulfide (H2S) Donors as Potent EGFR Inhibitors against L858R Resistance Mutation","volume":"202","author":"Zheng","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2020.104612_b0100","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2174\/1573409912666160126142236","article-title":"1-R-2-(1,2,4 Triazolo 1,5-c quinazoline-2-ylthio) etanon(ol) s: Synthesis, Bioluminescence Inhibition, Molecular Docking Studies, Antibacterial and Antifungal Activities","volume":"12","author":"Antypenko","year":"2016","journal-title":"Curr. Comput. Aided Drug Des."},{"key":"10.1016\/j.bioorg.2020.104612_b0105","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2174\/1871523018666190115092215","article-title":"Directed Search of Anti-inflammatory Agents among (3H-Quinazoline-4-ylidene) hydrazides of N-protected Amino acids and their Heterocyclization Products","volume":"19","author":"Yulya","year":"2020","journal-title":"Antiinflamm. Antiallergy Agents Med. Chem."},{"key":"10.1016\/j.bioorg.2020.104612_b0110","first-page":"1960","article-title":"Quinoline-Based Antifungals","volume":"17","author":"Musiol","year":"2010","journal-title":"Curr. Med."},{"key":"10.1016\/j.bioorg.2020.104612_b0115","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1021\/acs.jmedchem.7b00738","article-title":"Design and Synthesis of Orally Bioavailable Piperazine Substituted 4(1H)-Quinolones with Potent Antimalarial Activity: Structure-Activity and Structure-Property Relationship Studies","volume":"61","author":"Neelarapu","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2020.104612_b0120","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1016\/j.bmcl.2015.02.025","article-title":"Synthesis, anticonvulsant activity and molecular modelling study of some new hydrazinecarbothioamide, benzenesulfonohydrazide, and phenacylacetohydrazide analogues of 4(3H)-quinazolinone","volume":"25","author":"Al-Salem","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2020.104612_b0125","first-page":"100","article-title":"Design, synthesis, antimicrobial activity and anti-HIV activity evaluation of novel hybrid quinazoline-triazine derivatives","volume":"29","author":"Modh","year":"2014","journal-title":"J. EnzymeInhib. Med. Chem."},{"key":"10.1016\/j.bioorg.2020.104612_b0130","first-page":"733","article-title":"Synthesis and characterization of quinazoline derivatives: search for hybrid molecule as diuretic and antihypertensive agents","volume":"29","author":"Rahman","year":"2014","journal-title":"J. EnzymeInhib. Med. Chem."},{"key":"10.1016\/j.bioorg.2020.104612_b0135","doi-asserted-by":"crossref","first-page":"3","DOI":"10.32471\/exp-oncology.2312-8852.vol-41-no-1.12414","article-title":"Quinazoline compounds for antitumor treatment","volume":"41","author":"Solyanik","year":"2019","journal-title":"Exp. Oncol."},{"key":"10.1016\/j.bioorg.2020.104612_b0140","first-page":"138","article-title":"Narsaiah, Design and Synthesis of Novel Pyrimidine\/Hexahydroquinazoline-Fused Pyrazolo 3,4-b Pyridine Derivatives, Their Biological Evaluation and Docking Studies","volume":"4","author":"Ganapathi","year":"2019","journal-title":"Chem. Select."},{"key":"10.1016\/j.bioorg.2020.104612_b0145","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ejmech.2019.03.030","article-title":"2,4-Disubstituted quinazolines targeting breast cancer cells via EGFR-PI3K","volume":"172","author":"Li","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2020.104612_b0150","doi-asserted-by":"crossref","first-page":"24463","DOI":"10.1039\/C4RA01814A","article-title":"Recent advances in the synthesis of quinolines: a review","volume":"4","author":"Prajapati","year":"2014","journal-title":"RSC Adv."},{"key":"10.1016\/j.bioorg.2020.104612_b0155","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41372-019-0469-8","article-title":"Issues, challenges, and the way forward in conducting clinical trials among neonates: investigators\u2019 perspective","volume":"3","author":"Sivanandan","year":"2019","journal-title":"J. Perinatol."},{"key":"10.1016\/j.bioorg.2020.104612_b0160","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/0471140856.tx2006s47","article-title":"Caco- 2 cells as a model for intestinal absorption","volume":"47","author":"Angelis","year":"2011","journal-title":"Curr. Protoc. Toxicol."},{"key":"10.1016\/j.bioorg.2020.104612_b0165","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.addr.2012.09.019","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"64","author":"Lipinski","year":"2012","journal-title":"Adv. DrugDeliv. Rev."},{"key":"10.1016\/j.bioorg.2020.104612_b0170","doi-asserted-by":"crossref","first-page":"4533","DOI":"10.1016\/j.bmc.2015.06.008","article-title":"Structure Based Library Design (SBLD) for new 1,4-dihydropyrimidine scaffold as simultaneous COX-1\/COX-2 and 5-LOX inhibitors","volume":"23","author":"Lokwani","year":"2015","journal-title":"Bioorgan. Med. Chem."},{"key":"10.1016\/j.bioorg.2020.104612_b0175","doi-asserted-by":"crossref","first-page":"18621","DOI":"10.1039\/C8NJ04622K","article-title":"DIPEAc promoted one-pot synthesis of dihydropyrido[2,3-d:6,5-d\u2032]dipyrimidinetetraone and pyrimido[4,5-d]pyrimidine derivatives as potent tyrosinase inhibitors and anticancer agents: in vitro screening, molecular docking and ADMET predictions","volume":"42","author":"Bhosle","year":"2018","journal-title":"New J. Chem."},{"key":"10.1016\/j.bioorg.2020.104612_b0180","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/molecules23020440","article-title":"Ionic Liquid-Promoted Synthesis of Novel Chromone-Pyrimidine Coupled Derivatives, Antimicrobial Analysis, Enzyme Assay, Docking Study and Toxicity Study","volume":"23","author":"Tiwari","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2020.104612_b0185","first-page":"145","article-title":"Synthesis, antitumor screening and cell cycle analysis of novel benzothieno[3,2-b]pyran derivatives","volume":"31","author":"Zaher","year":"2016","journal-title":"J. EnzymeInhib. Med. Chem."},{"key":"10.1016\/j.bioorg.2020.104612_b0190","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1016\/j.ejmech.2017.10.075","article-title":"Design and synthesis of thienopyrimidine urea derivatives with potential cytotoxic and pro-apoptotic activity against breast cancer cell line MCF-7","volume":"143","author":"Abdelhaleem","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2020.104612_b0195","doi-asserted-by":"crossref","first-page":"7331","DOI":"10.1007\/s11164-017-3078-1","article-title":"Novel quinoline-based oxadiazole derivatives induce G2\/M arrest and apoptosis in human breast cancer MCF-7 cell line","volume":"43","author":"Dofe","year":"2017","journal-title":"Res. Chem. Intermed."},{"key":"10.1016\/j.bioorg.2020.104612_b0200","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.canlet.2010.01.029","article-title":"Cucurbitacin B induces apoptosis and S phase cell cycle arrest in BEL-7402 human hepatocellular carcinoma cells and is effective via oral administration","volume":"294","author":"Chan","year":"2010","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bioorg.2020.104612_b0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejmech.2019.111888","article-title":"Discovery of novel 9-heterocyclyl substituted 9H-purines as L858R\/T790M\/C797S mutant EGFR tyrosine kinase inhibitors","volume":"186","author":"Lei","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2020.104612_b0210","first-page":"153","article-title":"Novel 2-(nitrooxy)ethyl 2-(4-(substituted phenyl)-2-((substituted phenyl)amino)thiazol-5-yl)acetate as anti-inflammatory, analgesic and nitric oxide releasing agents: Synthesis and Molecular Docking studies","volume":"16","author":"Karnik","year":"2017","journal-title":"Antiinflamm. Antiallergy Agents Med. Chem."},{"key":"10.1016\/j.bioorg.2020.104612_b0215","article-title":"Development of triple mutant T790M\/C797S allosteric EGFR inhibitors: a computational approach","author":"Karnik","year":"2020","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.bioorg.2020.104612_b0220","first-page":"5756","article-title":"Auto QSAR- A Fast Approach for Creation and Application of QSAR Models through Automation","volume":"5","author":"Karnik","year":"2020","journal-title":"Chemistry select."},{"key":"10.1016\/j.bioorg.2020.104612_b0225","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1177\/1087057106296047","article-title":"Three mechanistically distinct kinase assays compared: measurement of intrinsic ATPase activity identified the most comprehensive set of ITK inhibitors","volume":"12","author":"Kashem","year":"2007","journal-title":"J. Biomol. Screen."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206820319106?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206820319106?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T08:16:17Z","timestamp":1758615377000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206820319106"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":45,"alternative-id":["S0045206820319106"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2020.104612","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Computational and Synthetic approach with Biological Evaluation of Substituted Quinoline derivatives as small molecule L858R\/T790M\/C797S triple mutant EGFR inhibitors targeting resistance in Non-Small Cell Lung Cancer (NSCLC)","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2020.104612","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104612"}}